Nuvectis Pharma initiates NXP900 Phase 1b, targets advanced cancers.

Nuvectis Pharma has initiated its Phase 1b NXP900 program for advanced cancers, aiming for preliminary clinical efficacy evidence. The Phase 1a dose escalation study successfully completed with robust pharmacodynamic responses at clinically relevant doses, enabling once-daily oral dosing. A clinical drug-drug interaction study in healthy volunteers has also been completed, supporting combination therapy strategies. Poster presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics highlight NXP900's emerging clinical profile.